2023 Fiscal Year Final Research Report
Identification of new therapeutic targets for glucose independent metabolism in breast cancer
| Project/Area Number |
20K08948
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 55010:General surgery and pediatric surgery-related
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
石田 孝宣 東北大学, 医学系研究科, 教授 (00292318)
古本 祥三 東北大学, サイクロトロン・ラジオアイソトープセンター, 教授 (00375198)
鈴木 貴 東北大学, 医学系研究科, 教授 (10261629)
|
|---|
| Project Period (FY) |
2020-04-01 – 2024-03-31
|
| Keywords | 乳癌 / アミノ酸代謝 / LAT1 / 分子イメージング |
|---|
| Outline of Final Research Achievements |
Cancer cells have glycolysis to maintain high proliferation, which is known as metabolic reprogramming, and it has been applied to FDG-PET. However, various metabolic pathways other than glycolysis are considered to exist, and we focused on the LAT1-mediated amino acid metabolism. In breast cancer, LATI expression was implicated in resistance to chemotherapy and endocrine therapy and correlated with prognosis, suggesting that LAT1 inhibitors are a novel therapeutic option.It was also found that amino acid-labelled radio tracers (18F-FETs) were taken up via LAT1, indicating their potential for diagnostic imaging applications that could confirm LAT1 expression in vivo.
|
| Free Research Field |
分子生物学
|
| Academic Significance and Societal Importance of the Research Achievements |
乳癌における代謝リプログラミングについては、糖代謝の報告が多く画像診断には利用されているものの、治療標的としての研究報告は少ない。本研究では、LAT1を介したアミノ酸代謝に着目し、乳癌においてその発現が薬剤耐性を惹起し予後不良となることが明らかとなり、LAT1を標的とする治療戦略が新たな選択肢になると考えられた。さらに、すでに胆道癌で臨床試験が行われているLAT1阻害薬(JOH203）は、in vitroで乳癌細胞の増殖抑制効果があることを示し、薬剤耐性乳癌における新規治療としの期待がもたれる。
|
